The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice
Open accessAbstract
Wnt signaling increases bone mass by stimulating osteoblast lineage commitment and expansion and forms the basis for novel anabolic therapeutic strategies being developed for osteoporosis. These strategies include derepression of Wnt signaling by targeting secreted Wnt pathway antagonists, such as sclerostin. However, such therapies are associated with safety concerns regarding an increased risk of osteosarcoma, the most common primary malignancy of bone. Here, we analyzed 5 human osteosarcoma cell lines in a high-throughput screen for epigenetically silenced tumor suppressor genes and identified Wnt inhibitory factor 1 (WIF1), which encodes an endogenous secreted Wnt pathway antagonist, as a candidate tumor suppressor gene. In vitro, WIF1 suppressed beta-catenin levels in human osteosarcoma cell lines, induced differentiation of human and mouse primary osteoblasts, and suppressed the growth of mouse and human osteosarcoma cell lines. Wif1 was highly expressed in the developing and mature mouse skeleton, and, although it was dispensable for normal development, targeted deletion of mouse Wif1 accelerated development of radiation-induced osteosarcomas in vivo. In primary human osteosarcomas, silencing of WIF1 by promoter hypermethylation was associated with loss of differentiation, increased beta-catenin levels, and increased proliferation. These data lead us to suggest that derepression of Wnt signaling by targeting secreted Wnt antagonists in osteoblasts may increase susceptibility to osteosarcoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia
Román-Gómez, J., Cordeu, L., Agirre, X., Jiménez-Velasco, A., San José-Eneriz, E., Garate, L., Calasanz, M. J., Heiniger, A., Torres, A., & Prosper, F. (2007) · Blood · doi:10.1182/blood-2006-09-047043 · Cited by 168
RetractedInternational Agency for Research on Cancer
National Cancer Institute (2020) · Definitions · doi:10.32388/pfg7jq · Cited by 9,435
β-Catenin regulates expression of cyclin D1 in colon carcinoma cells
Tetsu, O., & McCormick, F. (1999) · Nature · doi:10.1038/18884 · Cited by 3,601
Yang, Y. H. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.4.e15 · Cited by 3,464
Frommer, M., McDonald, L. E., Millar, D. S., Collis, C. M., Watt, F., Grigg, G. W., Molloy, P. L., & Paul, C. L. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.5.1827 · Cited by 3,238
Derivation of completely cell culture-derived mice from early-passage embryonic stem cells.
Nagy, A., Rossant, J., Nagy, R., Abramow-Newerly, W., & Roder, J. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8424 · Cited by 2,329
LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development
Gong, Y., Slee, R. B., Fukai, N., Rawadi, G., Roman-Roman, S., Reginato, A. M., Wang, H., Cundy, T., Glorieux, F. H., Lev, D., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00571-2 · Cited by 2,235
Pathology and genetics of tumours of soft tissue and bone
Fletcher, C. D. �., Unni, K. K., & Mertens, F. (2002) · Medical Entomology and Zoology · Cited by 2,073
Improved retroviral vectors for gene transfer and expression.
Miller, A. D., & Rosman, G. J. (1989) · PubMed · Cited by 1,971
DNA hypermethylation in tumorigenesis: epigenetics joins genetics
Baylin, S. B., & Herman, J. G. (2000) · Trends in Genetics · doi:10.1016/s0168-9525(99)01971-x · Cited by 1,628
Cited by
Osteoporosis: now and the future
Rachner, T. D., Khosla, S., & Hofbauer, L. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62349-5 · Cited by 2,696
WNT signaling in bone homeostasis and disease: From human mutations to treatments
Baron, R., & Kneissel, M. (2013) · Nature Medicine · doi:10.1038/nm.3074 · Cited by 2,093
WNT signalling pathways as therapeutic targets in cancer
Anastas, J. N., & Moon, R. T. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3419 · Cited by 1,911
Translational biology of osteosarcoma
Kansara, M., Teng, M. W., Smyth, M. J., & Thomas, D. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3838 · Cited by 1,294
Self-citationSecreted and transmembrane wnt inhibitors and activators
Cruciat, C.-M., & Niehrs, C. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a015081 · Cited by 646
Sclerostin and Dickkopf-1 as Therapeutic Targets in Bone Diseases
Ke, H. Z., Richards, W. G., Li, X., & Ominsky, M. S. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1060 · Cited by 402
Update on Wnt signaling in bone cell biology and bone disease
Monroe, D. G., McGee-Lawrence, M. E., Oursler, M. J., & Westendorf, J. J. (2012) · Gene · doi:10.1016/j.gene.2011.10.044 · Cited by 392
Wnt signaling in bone formation and its therapeutic potential for bone diseases
Kim, J. H., Liu, X., Wang, J., Chen, X., Zhang, H., Kim, S. H., Cui, J., Li, R., Zhang, W., Kong, Y., et al. (2013) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x12466608 · Cited by 356
The Regulation of Bone Metabolism and Disorders by Wnt Signaling
Maeda, K., Kobayashi, Y., Koide, M., Uehara, S., Okamoto, M., Ishihara, A., Kayama, T., Saito, M., & Marumo, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225525 · Cited by 353
Molecular Biology of Osteosarcoma
Czarnecka, A. M., Synoradzki, K., Firlej, W., Bartnik, E., Sobczuk, P., Fiedorowicz, M., Grieb, P., & Rutkowski, P. (2020) · Cancers · doi:10.3390/cancers12082130 · Cited by 336
Sclerostin: Current Knowledge and Future Perspectives
Moester, M. J. C., Papapoulos, S. E., Löwik, C. W. G. M., & van Bezooijen, R. L. (2010) · Calcified Tissue International · doi:10.1007/s00223-010-9372-1 · Cited by 332
Mechanisms of bone repair and regeneration
Deschaseaux, F., Sensébé, L., & Heymann, D. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.07.002 · Cited by 324
Update on Bone Anabolics in Osteoporosis Treatment: Rationale, Current Status, and Perspectives
Baron, R., & Hesse, E. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2332 · Cited by 320
Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches
Canalis, E. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.154 · Cited by 304
Mohammed, M. K., Shao, C., Wang, J., Wei, Q., Wang, X., Collier, Z., Tang, S., Liu, H., Zhang, F., Huang, J., et al. (2016) · Genes & Diseases · doi:10.1016/j.gendis.2015.12.004 · Cited by 259
Cells of origin in osteosarcoma: Mesenchymal stem cells or osteoblast committed cells?
Mutsaers, A. J., & Walkley, C. R. (2014) · Bone · doi:10.1016/j.bone.2014.02.003 · Cited by 233
“To date a range of studies have comparedOS to a number of different controls for transcriptional profiling (MSCs, differentiated osteoblasts, mixed cultures of osteoblasts) [36,76–79].”
BackgroundWei, J., Fang, F., Lam, A. P., Sargent, J. L., Hamburg, E., Hinchcliff, M. E., Gottardi, C. J., Atit, R., Whitfield, M. L., & Varga, J. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34424 · Cited by 226
The Architecture and Evolution of Cancer Neochromosomes
Garsed, D. W., Marshall, O. J., Corbin, V. D. A., Hsu, A., Di Stefano, L., Schröder, J., Li, J., Feng, Z.-P., Kim, B. W., Kowarsky, M., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.010 · Cited by 194
Self-citationVlashi, R., Zhang, X., Wu, M., & Chen, G. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.07.011 · Cited by 165
“However, WIF-1 methylation is associated with bone tumors although it is epigenetically silenced in human osteosarcoma cell lines.(190) Ultimately, a documentation of the roles of most Wnt signaling pathway constituents during osteoblastogenesis,”
BackgroundGorlick, R., & Khanna, C. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.77 · Cited by 157
Svegliati, S., Marrone, G., Pezone, A., Spadoni, T., Grieco, A., Moroncini, G., Grieco, D., Vinciguerra, M., Agnese, S., Jüngel, A., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2004592 · Cited by 100
Update in new anabolic therapies for osteoporosis
Canalis, E. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2677 · Cited by 85
Goldstein, S. D., Trucco, M., Guzman, W. B., Hayashi, M., & Loeb, D. M. (2016) · Oncotarget · doi:10.18632/oncotarget.8522 · Cited by 78
“For example, Kansara and colleagues reported that WIF1 is epigenetically silenced in human osteosarcoma cell lines [11].”
BackgroundOsteosarcomagenesis: Modeling Cancer Initiation in the Mouse
Jones, K. B. (2011) · Sarcoma · doi:10.1155/2011/694136 · Cited by 40
RECQ DNA Helicases and Osteosarcoma
Lu, L., Jin, W., & Wang, L. L. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-43085-6_3 · Cited by 28
Metadata
- Authors
- Kansara, M., Tsang, M., Kodjabachian, L., Sims, N. A., Trivett, M. K., Ehrich, M., Dobrovic, A., Slavin, J., Choong, P. F. M., Simmons, P. J., Dawid, I. B., & Thomas, D. M.
- Venue
- Journal of Clinical Investigation
- Published
- 2009-04-01
- Volume
- 119
- Issue
- 4
- Pages
- 837-851
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2008432341
- Cited by
- 272
- References
- 65
- FWCI
- 10.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.